Investors & Media

Investors & Media

About Immatics

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. 

 

Stock Quote

Immatics N.V.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press & Media

Immatics beginnt klinische Phase-1-Studie zur Untersuchung des bispezifischen TCR-Kandidaten IMA401 bei Patienten mit fortgeschrittenen soliden Tumoren

read more

Immatics veröffentlicht Ergebnisse des Geschäftsjahres 2021 sowie ein Update zur Geschäftsentwicklung

read more

Immatics und Bristol Myers Squibb schließen weltweite Exklusivlizenz für Immatics‘ bispezifisches TCR-Programm IMA401 ab

read more